Verteporfin has been explored as a potential inhibitor that hampers IFN-γ-derived PD-L1 expression by disrupting the STAT1-IRF1-TRIM28 signaling cascade T-cell leukemia, B-cell leukemia, ovarian, osteoblastoma, and NSCLC [251]. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.